28.8 C
New York
Wednesday, June 3, 2026

Tag: trial

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it...

In HelloNation, Hearing Expert Allison Liberio Explains Hearing Aid Cost in Southlake, Texas

The article breaks down pricing factors and helps readers understand what influences hearing aid expenses.SOUTHLAKE, Texas, June 3, 2026 /PRNewswire/ -- What should residents...

Glenn Agre Bergman & Fuentes Builds Out Structured Financial Products Litigation Practice with New Lateral Partner

Zachary W. Mazin joins from McKool Smith, deepening the firm's capabilities at the intersection of complex financial fraud, restructuring and accounting malpractice litigationNEW YORK,...

SweetNight Launches CoolNest® Pro, an Upgraded Memory Foam Mattress Engineered for Hot Sleepers

Upgraded four-stage cooling system and 7-zone support target the most common cause of disrupted sleep in American homesWILMINGTON, Del., June 3, 2026 /PRNewswire/ --...

ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...

OZOP Energy Solutions, Inc. Highlights Major Cultural Milestone as Unity Electro Fest Unveils 2026 Lineup Featuring Tiësto, Illenium, and Timmy Trumpet

WARWICK, NY, June 03, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today highlighted a major cultural milestone at Unity Electro Fest, a large-scale Canadian electronic music festival in which Varon Wellness, a subsidiary of Varon Corp, holds a strategic ownership interest. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP..

1606 Corp. Advances Power Acquisition as Financing Discussions Accelerate

1606 Corp. Advances Power Acquisition as Financing Discussions Accelerate

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented
Further clinical efficacy and pharmacology data also to be presented

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial